A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders.

more…


Leave a Reply

Your email address will not be published.

Popular Blog Posts

The Pandemic, Teen Depression, and Suicide Risk

End The Stigma!

Lady Gaga and Bradley Cooper did a masterful remake of “A Star is Born”, now in theaters. We highly…

LEARN MORE

Dr. Sanjay Gupta on CNN: “Ketamine offers lifeline for people with severe depression, suicidal thoughts”

In this post, a Wisconsin man who had been on the brink of suicide, told CNN’s Sanjay Gupta how…

LEARN MORE

The Resurgence of Psychedelics in Medicine

There has been a flurry of articles in the media recently touting the successful use of psychedelics in medicine.…

LEARN MORE

Ketamine Infusions Provide Effective Relief for Severe Chronic Headache

Medical research is revealing more and more applications for ketamine, the old drug being used in new ways. Just…

LEARN MORE

New Insight Into How Ketamine Works in Depression

Ketamine exerts an initial antidepressant effect by blocking the N-methyl-D-aspartate receptor (NMDAR), and the ketamine metabolite hydroxynorketamine (HNK) may extend…

LEARN MORE